Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Identifieur interne : 000C19 ( Main/Exploration ); précédent : 000C18; suivant : 000C20Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Auteurs : R. Bell [Australie] ; J. Brown [Royaume-Uni] ; M. Parmar [Royaume-Uni] ; M. Toi [Japon] ; T. Suter [Suisse] ; G G Steger [Autriche] ; X. Pivot [France] ; J. Mackey [Canada] ; C. Jackisch [Allemagne] ; R. Dent [Canada] ; P. Hall [Royaume-Uni] ; N. Xu [Suisse] ; L. Morales [Suisse] ; L. Provencher [Canada] ; R. Hegg [Brésil] ; L. Vanlemmens [France] ; A. Kirsch [Allemagne] ; A. Schneeweiss [Allemagne] ; N. Masuda [Japon] ; F. Overkamp [Allemagne] ; D. Cameron [Royaume-Uni]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Bévacizumab (administration et posologie), Bévacizumab (effets indésirables), Estimation de Kaplan-Meier, Femelle, Humains, Modèles de hasards proportionnels, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Survie sans rechute, Traitement médicamenteux adjuvant (), Tumeurs du sein triple-négatives (mortalité), Tumeurs du sein triple-négatives (traitement médicamenteux).
- MESH :
- administration et posologie : Bévacizumab.
- effets indésirables : Bévacizumab.
- mortalité : Tumeurs du sein triple-négatives.
- traitement médicamenteux : Tumeurs du sein triple-négatives.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Femelle, Humains, Modèles de hasards proportionnels, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bevacizumab (administration & dosage), Bevacizumab (adverse effects), Chemotherapy, Adjuvant (methods), Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Treatment Outcome, Triple Negative Breast Neoplasms (drug therapy), Triple Negative Breast Neoplasms (mortality).
- MESH :
- chemical , administration & dosage : Bevacizumab.
- chemical , adverse effects : Bevacizumab.
- drug therapy : Triple Negative Breast Neoplasms.
- methods : Chemotherapy, Adjuvant.
- mortality : Triple Negative Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Treatment Outcome.
Abstract
The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC).
DOI: 10.1093/annonc/mdw665
PubMed: 27993816
Affiliations:
- Allemagne, Australie, Autriche, Brésil, Canada, France, Japon, Royaume-Uni, Suisse
- Angleterre, Bade-Wurtemberg, Berlin, Bourgogne-Franche-Comté, Canton de Berne, District de Karlsruhe, District de Münster, Franche-Comté, Grand Londres, Hauts-de-France, Nord-Pas-de-Calais, Ontario, Rhénanie-du-Nord-Westphalie, Région du Kansai, Vienne (Autriche), Yorkshire-et-Humber, Écosse, État de São Paulo
- Berlin, Berne, Besançon, Heidelberg, Kyoto, Leeds, Lille, Londres, Recklinghausen (Ruhr), São Paulo, Toronto, Vienne (Autriche), Édimbourg
- Université de Kyoto, Université de Leeds, Université de Toronto
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E06
- to stream PubMed, to step Curation: 000E03
- to stream PubMed, to step Checkpoint: 000E03
- to stream Ncbi, to step Merge: 004061
- to stream Ncbi, to step Curation: 004061
- to stream Ncbi, to step Checkpoint: 004061
- to stream Main, to step Merge: 000C14
- to stream Main, to step Curation: 000C19
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.</title><author><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R" last="Bell">R. Bell</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Deakin University, Geelong, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Deakin University, Geelong</wicri:regionArea><wicri:noRegion>Geelong</wicri:noRegion></affiliation></author><author><name sortKey="Brown, J" sort="Brown, J" uniqKey="Brown J" first="J" last="Brown">J. Brown</name><affiliation wicri:level="4"><nlm:affiliation>Clinical Trials Research Unit, University of Leeds, Leeds.</nlm:affiliation><orgName type="university">Université de Leeds</orgName><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author><author><name sortKey="Parmar, M" sort="Parmar, M" uniqKey="Parmar M" first="M" last="Parmar">M. Parmar</name><affiliation wicri:level="3"><nlm:affiliation>Medical Research Council Clinical Trials Unit, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Toi, M" sort="Toi, M" uniqKey="Toi M" first="M" last="Toi">M. Toi</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Kyoto University, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Medicine, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Suter, T" sort="Suter, T" uniqKey="Suter T" first="T" last="Suter">T. Suter</name><affiliation wicri:level="3"><nlm:affiliation>Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Cardiovascular Center, Bern University Hospital, Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Steger, G G" sort="Steger, G G" uniqKey="Steger G" first="G G" last="Steger">G G Steger</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Pivot, X" sort="Pivot, X" uniqKey="Pivot X" first="X" last="Pivot">X. Pivot</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Service, University Hospital Jean Minjoz, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Service, University Hospital Jean Minjoz, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName></affiliation></author><author><name sortKey="Mackey, J" sort="Mackey, J" uniqKey="Mackey J" first="J" last="Mackey">J. Mackey</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, Cross Center Institute, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Oncology, Cross Center Institute, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation></author><author><name sortKey="Jackisch, C" sort="Jackisch, C" uniqKey="Jackisch C" first="C" last="Jackisch">C. Jackisch</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach</wicri:regionArea><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="Dent, R" sort="Dent, R" uniqKey="Dent R" first="R" last="Dent">R. Dent</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Hall, P" sort="Hall, P" uniqKey="Hall P" first="P" last="Hall">P. Hall</name><affiliation wicri:level="4"><nlm:affiliation>Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds Institute of Health Sciences, University of Leeds, Leeds</wicri:regionArea><orgName type="university">Université de Leeds</orgName><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author><author><name sortKey="Xu, N" sort="Xu, N" uniqKey="Xu N" first="N" last="Xu">N. Xu</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Morales, L" sort="Morales, L" uniqKey="Morales L" first="L" last="Morales">L. Morales</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Provencher, L" sort="Provencher, L" uniqKey="Provencher L" first="L" last="Provencher">L. Provencher</name><affiliation wicri:level="1"><nlm:affiliation>Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Perola Byington Hospital/FMUSP, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Oncology Department, Perola Byington Hospital/FMUSP, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Vanlemmens, L" sort="Vanlemmens, L" uniqKey="Vanlemmens L" first="L" last="Vanlemmens">L. Vanlemmens</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Centre Oscar Lambret, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Centre Oscar Lambret, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kirsch, A" sort="Kirsch, A" uniqKey="Kirsch A" first="A" last="Kirsch">A. Kirsch</name><affiliation wicri:level="3"><nlm:affiliation>Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Schneeweiss, A" sort="Schneeweiss, A" uniqKey="Schneeweiss A" first="A" last="Schneeweiss">A. Schneeweiss</name><affiliation wicri:level="3"><nlm:affiliation>Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Masuda, N" sort="Masuda, N" uniqKey="Masuda N" first="N" last="Masuda">N. Masuda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Overkamp, F" sort="Overkamp, F" uniqKey="Overkamp F" first="F" last="Overkamp">F. Overkamp</name><affiliation wicri:level="3"><nlm:affiliation>Oncologianova, Recklinghausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Oncologianova, Recklinghausen</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Münster</region><settlement type="city">Recklinghausen (Ruhr)</settlement></placeName></affiliation></author><author><name sortKey="Cameron, D" sort="Cameron, D" uniqKey="Cameron D" first="D" last="Cameron">D. Cameron</name><affiliation wicri:level="3"><nlm:affiliation>Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27993816</idno><idno type="pmid">27993816</idno><idno type="doi">10.1093/annonc/mdw665</idno><idno type="wicri:Area/PubMed/Corpus">000E06</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E06</idno><idno type="wicri:Area/PubMed/Curation">000E03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E03</idno><idno type="wicri:Area/PubMed/Checkpoint">000E03</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E03</idno><idno type="wicri:Area/Ncbi/Merge">004061</idno><idno type="wicri:Area/Ncbi/Curation">004061</idno><idno type="wicri:Area/Ncbi/Checkpoint">004061</idno><idno type="wicri:Area/Main/Merge">000C14</idno><idno type="wicri:Area/Main/Curation">000C19</idno><idno type="wicri:Area/Main/Exploration">000C19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.</title><author><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R" last="Bell">R. Bell</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Deakin University, Geelong, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Deakin University, Geelong</wicri:regionArea><wicri:noRegion>Geelong</wicri:noRegion></affiliation></author><author><name sortKey="Brown, J" sort="Brown, J" uniqKey="Brown J" first="J" last="Brown">J. Brown</name><affiliation wicri:level="4"><nlm:affiliation>Clinical Trials Research Unit, University of Leeds, Leeds.</nlm:affiliation><orgName type="university">Université de Leeds</orgName><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author><author><name sortKey="Parmar, M" sort="Parmar, M" uniqKey="Parmar M" first="M" last="Parmar">M. Parmar</name><affiliation wicri:level="3"><nlm:affiliation>Medical Research Council Clinical Trials Unit, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Toi, M" sort="Toi, M" uniqKey="Toi M" first="M" last="Toi">M. Toi</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Kyoto University, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Medicine, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Suter, T" sort="Suter, T" uniqKey="Suter T" first="T" last="Suter">T. Suter</name><affiliation wicri:level="3"><nlm:affiliation>Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Cardiovascular Center, Bern University Hospital, Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Steger, G G" sort="Steger, G G" uniqKey="Steger G" first="G G" last="Steger">G G Steger</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Pivot, X" sort="Pivot, X" uniqKey="Pivot X" first="X" last="Pivot">X. Pivot</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Service, University Hospital Jean Minjoz, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Service, University Hospital Jean Minjoz, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName></affiliation></author><author><name sortKey="Mackey, J" sort="Mackey, J" uniqKey="Mackey J" first="J" last="Mackey">J. Mackey</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, Cross Center Institute, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Oncology, Cross Center Institute, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation></author><author><name sortKey="Jackisch, C" sort="Jackisch, C" uniqKey="Jackisch C" first="C" last="Jackisch">C. Jackisch</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach</wicri:regionArea><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="Dent, R" sort="Dent, R" uniqKey="Dent R" first="R" last="Dent">R. Dent</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Hall, P" sort="Hall, P" uniqKey="Hall P" first="P" last="Hall">P. Hall</name><affiliation wicri:level="4"><nlm:affiliation>Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds Institute of Health Sciences, University of Leeds, Leeds</wicri:regionArea><orgName type="university">Université de Leeds</orgName><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author><author><name sortKey="Xu, N" sort="Xu, N" uniqKey="Xu N" first="N" last="Xu">N. Xu</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Morales, L" sort="Morales, L" uniqKey="Morales L" first="L" last="Morales">L. Morales</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Provencher, L" sort="Provencher, L" uniqKey="Provencher L" first="L" last="Provencher">L. Provencher</name><affiliation wicri:level="1"><nlm:affiliation>Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Perola Byington Hospital/FMUSP, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Oncology Department, Perola Byington Hospital/FMUSP, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Vanlemmens, L" sort="Vanlemmens, L" uniqKey="Vanlemmens L" first="L" last="Vanlemmens">L. Vanlemmens</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Centre Oscar Lambret, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Centre Oscar Lambret, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kirsch, A" sort="Kirsch, A" uniqKey="Kirsch A" first="A" last="Kirsch">A. Kirsch</name><affiliation wicri:level="3"><nlm:affiliation>Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Schneeweiss, A" sort="Schneeweiss, A" uniqKey="Schneeweiss A" first="A" last="Schneeweiss">A. Schneeweiss</name><affiliation wicri:level="3"><nlm:affiliation>Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Masuda, N" sort="Masuda, N" uniqKey="Masuda N" first="N" last="Masuda">N. Masuda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Overkamp, F" sort="Overkamp, F" uniqKey="Overkamp F" first="F" last="Overkamp">F. Overkamp</name><affiliation wicri:level="3"><nlm:affiliation>Oncologianova, Recklinghausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Oncologianova, Recklinghausen</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Münster</region><settlement type="city">Recklinghausen (Ruhr)</settlement></placeName></affiliation></author><author><name sortKey="Cameron, D" sort="Cameron, D" uniqKey="Cameron D" first="D" last="Cameron">D. Cameron</name><affiliation wicri:level="3"><nlm:affiliation>Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bevacizumab (administration & dosage)</term><term>Bevacizumab (adverse effects)</term><term>Chemotherapy, Adjuvant (methods)</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Treatment Outcome</term><term>Triple Negative Breast Neoplasms (drug therapy)</term><term>Triple Negative Breast Neoplasms (mortality)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bévacizumab (administration et posologie)</term><term>Bévacizumab (effets indésirables)</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant ()</term><term>Tumeurs du sein triple-négatives (mortalité)</term><term>Tumeurs du sein triple-négatives (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bevacizumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bevacizumab</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bévacizumab</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Bévacizumab</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC).</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Brésil</li><li>Canada</li><li>France</li><li>Japon</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>Berlin</li><li>Bourgogne-Franche-Comté</li><li>Canton de Berne</li><li>District de Karlsruhe</li><li>District de Münster</li><li>Franche-Comté</li><li>Grand Londres</li><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li><li>Ontario</li><li>Rhénanie-du-Nord-Westphalie</li><li>Région du Kansai</li><li>Vienne (Autriche)</li><li>Yorkshire-et-Humber</li><li>Écosse</li><li>État de São Paulo</li></region><settlement><li>Berlin</li><li>Berne</li><li>Besançon</li><li>Heidelberg</li><li>Kyoto</li><li>Leeds</li><li>Lille</li><li>Londres</li><li>Recklinghausen (Ruhr)</li><li>São Paulo</li><li>Toronto</li><li>Vienne (Autriche)</li><li>Édimbourg</li></settlement><orgName><li>Université de Kyoto</li><li>Université de Leeds</li><li>Université de Toronto</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R" last="Bell">R. Bell</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brown, J" sort="Brown, J" uniqKey="Brown J" first="J" last="Brown">J. Brown</name></region><name sortKey="Cameron, D" sort="Cameron, D" uniqKey="Cameron D" first="D" last="Cameron">D. Cameron</name><name sortKey="Hall, P" sort="Hall, P" uniqKey="Hall P" first="P" last="Hall">P. Hall</name><name sortKey="Parmar, M" sort="Parmar, M" uniqKey="Parmar M" first="M" last="Parmar">M. Parmar</name></country><country name="Japon"><region name="Région du Kansai"><name sortKey="Toi, M" sort="Toi, M" uniqKey="Toi M" first="M" last="Toi">M. Toi</name></region><name sortKey="Masuda, N" sort="Masuda, N" uniqKey="Masuda N" first="N" last="Masuda">N. Masuda</name></country><country name="Suisse"><region name="Canton de Berne"><name sortKey="Suter, T" sort="Suter, T" uniqKey="Suter T" first="T" last="Suter">T. Suter</name></region><name sortKey="Morales, L" sort="Morales, L" uniqKey="Morales L" first="L" last="Morales">L. Morales</name><name sortKey="Xu, N" sort="Xu, N" uniqKey="Xu N" first="N" last="Xu">N. Xu</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Steger, G G" sort="Steger, G G" uniqKey="Steger G" first="G G" last="Steger">G G Steger</name></region></country><country name="France"><region name="Bourgogne-Franche-Comté"><name sortKey="Pivot, X" sort="Pivot, X" uniqKey="Pivot X" first="X" last="Pivot">X. Pivot</name></region><name sortKey="Vanlemmens, L" sort="Vanlemmens, L" uniqKey="Vanlemmens L" first="L" last="Vanlemmens">L. Vanlemmens</name></country><country name="Canada"><noRegion><name sortKey="Mackey, J" sort="Mackey, J" uniqKey="Mackey J" first="J" last="Mackey">J. Mackey</name></noRegion><name sortKey="Dent, R" sort="Dent, R" uniqKey="Dent R" first="R" last="Dent">R. Dent</name><name sortKey="Provencher, L" sort="Provencher, L" uniqKey="Provencher L" first="L" last="Provencher">L. Provencher</name></country><country name="Allemagne"><noRegion><name sortKey="Jackisch, C" sort="Jackisch, C" uniqKey="Jackisch C" first="C" last="Jackisch">C. Jackisch</name></noRegion><name sortKey="Kirsch, A" sort="Kirsch, A" uniqKey="Kirsch A" first="A" last="Kirsch">A. Kirsch</name><name sortKey="Overkamp, F" sort="Overkamp, F" uniqKey="Overkamp F" first="F" last="Overkamp">F. Overkamp</name><name sortKey="Schneeweiss, A" sort="Schneeweiss, A" uniqKey="Schneeweiss A" first="A" last="Schneeweiss">A. Schneeweiss</name></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27993816
|texte= Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27993816" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |